Advanced in Embryonal Tumor with Multilayered Rosettes
Advanced in Embryonal Tumor with Multilayered Rosettes
7777 Forest Lane Suite, D400, 
Dallas, TX 

Overview

Stanton Goldman is a Pediatrics provider in Dallas, Texas. Dr. Goldman has been practicing medicine for over 35 years and is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Langerhans Cell Histiocytosis, Histiocytosis, Reticulohistiocytoma, Bone Marrow Aspiration, and Bone Marrow Transplant.

His clinical research consists of co-authoring 17 peer reviewed articles and participating in 58 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has participated in 21 clinical trials in the study of Embryonal Tumor with Multilayered Rosettes.

Graduate Institution
Boston University School Of Medicine, 1990
Residency
Pediatrics, Childrens National Medical Center DC
Specialties
Pediatrics
Licenses
Pediatric Hematology-Oncology in TX
Board Certifications
The American Board Of Pediatrics
Fellowships
Pediatric Hem/Onc, Johns Hopkins Hospital
Pediatric Hematology/Oncology, Johns Hopkins Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Cook Children's Health Plan
  • MANAGED MEDICAID PLAN
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Scott and White Health
  • HMO
  • POS
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
View 13 Less Insurance Carriers -

Locations

Texas Oncology, P.A.
7777 Forest Lane Suite, D400, Dallas, TX 75230

Additional Areas of Focus

Dr. Goldman has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


58 Clinical Trials

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or ALK Inhibitor Therapy Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)
A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations
Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)
Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphoma (B-LLy)
A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Treatment of Children With All Stages of Hepatoblastoma With Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
A Randomized Phase 3 Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Young Adults
Renal Tumors Classification, Biology, and Banking Study
Key Adverse Events After Childhood Cancer
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (IND# 133688, NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement
A Phase III Study for Patients With Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid
View 43 Less Clinical Trials
Similar Doctors
Experienced in Embryonal Tumor with Multilayered Rosettes
Pediatric Cardiology | Pediatrics
Experienced in Embryonal Tumor with Multilayered Rosettes
Pediatric Cardiology | Pediatrics

University Of Texas Southwestern Medical Center At Dallas

1935 Medical District Dr, 
Dallas, TX 
 (111.0 miles away)
Languages Spoken:
English

Hoang Nguyen is a Pediatric Cardiologist and a Pediatrics provider in Dallas, Texas. Dr. Nguyen is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Hypoplastic Left Heart Syndrome (HLHS), Mitral Atresia, Double Inlet Left Ventricle, and Fainting.

Experienced in Embryonal Tumor with Multilayered Rosettes
Pediatrics | Pediatric Radiology
Experienced in Embryonal Tumor with Multilayered Rosettes
Pediatrics | Pediatric Radiology

University Of Texas Southwestern Medical Center At Dallas

6201 Harry Hines Blvd, 
Dallas, TX 
 (111.5 miles away)
Languages Spoken:
English

Jeffrey Sorelle is a Pediatrics specialist and a Pediatric Radiologist in Dallas, Texas. Dr. Sorelle is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. His top areas of expertise are Cerebral Hypoxia, Pediatric Low-Grade Glioma (pLGG), Embryonal Tumor with Multilayered Rosettes, Islet Cell Transplantation, and Hormone Replacement Therapy (HRT).

Experienced in Embryonal Tumor with Multilayered Rosettes
Pediatric Neurology | Pediatrics | Neurology
Experienced in Embryonal Tumor with Multilayered Rosettes
Pediatric Neurology | Pediatrics | Neurology

University Of Texas Southwestern Medical Center At Dallas

1935 Medical District Dr, 
Dallas, TX 
 (111.0 miles away)
Languages Spoken:
English

Lauren Dengle is a Pediatric Neurologist and a Pediatrics provider in Dallas, Texas. Dr. Dengle is rated as an Advanced provider by MediFind in the treatment of Embryonal Tumor with Multilayered Rosettes. Her top areas of expertise are Neurofibromatosis Type 1 (NF1), Neurofibromatosis, Tourette Syndrome, and Optic Glioma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Goldman's expertise for a condition
ConditionClose
      View All 19 Advanced Conditions
      View All 14 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile